Announcements Trials
Browse Landscape

Phase

Phase 2 1Phase 1/2 1Phase 1 1

Status

Completed 16Terminated 10Recruiting 9Active not recruiting 6Withdrawn 3

Sponsor Class

OTHER 2INDUSTRY 1

Study Type

Interventional 3

Sponsor

Cancer Type

Dermatologic 3CNS 1

Conditions

Carcinoma, Non-Small-Cell Lung 14Brain Neoplasms 10Carcinoma, Hepatocellular 9Neoplasm Metastasis 7Neoplasms 6Pancreatic Neoplasms 5Lung Neoplasms 5Colorectal Neoplasms 4Squamous Cell Carcinoma of Head and Neck 3Prostatic Neoplasms 3Melanoma 3Carcinoma, Renal Cell 3Breast Neoplasms 3Glioblastoma 2Adenocarcinoma of Lung 2Triple Negative Breast Neoplasms 1Sarcoma 1Recurrence 1Radiotherapy 1Prostate Cancer Metastatic 1Ovarian Neoplasms 1Neoplasm, Residual 1Lymphoma, Non-Hodgkin 1Lymphoma, Follicular 1Liver Neoplasms 1Liver Diseases 1Kidney Neoplasms 1Glioma 1Carcinoma, Transitional Cell 1Carcinoma, Merkel Cell 1

Interventions

Nivolumab 17Ipilimumab 14pembrolizumab 11Cyclophosphamide 8trametinib 7dabrafenib 6Interleukin-2 6aldesleukin 5Vemurafenib 5Radiotherapy 5sargramostim 4130-nm albumin-bound paclitaxel 4fludarabine 3encorafenib 3binimetinib 3Specimen Handling 3Radiosurgery 3Melphalan 3Granulocyte-Macrophage Colony-Stimulating Factor 3fludarabine phosphate 2Magnetic Resonance Spectroscopy 2Introns 2Infliximab 2Celecoxib 2CTLA-4 Antigen 2Biopsy 2Bevacizumab 2Albumin-Bound Paclitaxel 2yeast-CEA vaccine 1vitespin 1

Date Range

30 days90 days1 yearAll

Options

Has results Has announcements

Clinical Trials

3 trials
RecentStart dateEnrollment
Withdrawn × Melanoma × Radiosurgery × Clear all
NCT02145910 2025-05-02

Vemurafenib Combined With Whole Brain Radiation Therapy or Radiosurgery in Patients With BRAF Mutation-Positive Melanoma and Brain Metastases

Thomas Jefferson University

Phase 1 Withdrawn
CNSDermatologic

Brain Neoplasms, Melanoma

NCT03167177 2025-02-21

QUILT-3.046: NANT Melanoma Vaccine: Combination Immunotherapy in Subjects With Melanoma Who Have Progressed On or After Chemotherapy and PD-1/PD-L1 Therapy

ImmunityBio, Inc.

Phase 1/2 Withdrawn
Dermatologic

Melanoma

NCT04042506 2021-04-12

SBRT as a Vaccination for Metastatic Melanoma

Sidney Kimmel Comprehensive Cancer Center at Johns Hopkins

Phase 2 Withdrawn
Dermatologic

Melanoma

Data powered by HemOnc (CC BY 4.0) Colophon âš¡